A Study of AZD8233 in Participants With Dyslipidemia.
Status:
Recruiting
Trial end date:
2022-04-20
Target enrollment:
Participant gender:
Summary
A Phase 1 and 2 Study of AZD8233 in Participants with Dyslipidemia and this study consists of
Part A and Part B. Part A is designed as a randomized, single-blind (blinding of participants
and sites), placebo-controlled, multiple dose, phase 1 study. Part B is designed as a
randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study.